A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

Yuh Min Chen, Reury Perng Perng, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Both gemcitabine and UFUR (UFT, tegafur/uracil) are effective agents against chemo-naïve non-small-cell lung cancer (NSCLC). Their effectiveness in patients failing previous chemotherapy is uncertain. Our aim was to evaluate the efficacy of gemcitabine plus UFUR in NSCLC patients who failed previous platinum-based chemotherapy. Forty-five patients were enrolled. The performance status was 1 in 29 patients and 2 in 16 patients. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on days 1 and 8, plus oral UFUR 200 mg/m2/day from days 1 to 14 of every 3 weeks, to a maximum of six cycles, carried out in the outpatient clinic. One hundred and sixty cycles of treatment were given (mean 3.6 cycles per patient). Grade 3 or 4 toxicities included anemia in four patients, leukopenia in three patients, neutropenia in eight patients, thrombocytopenia in four patients, and fatigue in two patients. After two cycles of treatment, seven of 45 patients (15.6%) had a partial response. The median survival was 13.2 months. Survival was better in those with a better performance status (p = 0.0006), in those with disease control using the present treatment (p < 0.0001), and in those who received Iressa or Tarceva as salvage therapy after failing the present treatment (p = 0.0054). In conclusion, salvage chemotherapy using gemcitabine plus UFUR is active, easy to use, and well tolerated in NSCLC patients who have failed previous chemotherapy. Further treatment with EGFR-TKI is also suggested when patients fail the present treatment.

Original languageEnglish
Pages (from-to)333-338
Number of pages6
JournalLung Cancer
Volume52
Issue number3
DOIs
Publication statusPublished - Jun 1 2006
Externally publishedYes

Fingerprint

gemcitabine
Tegafur
Uracil
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Therapeutics

Keywords

  • EGFR (epidermal growth factor receptor)
  • Gemcitabine
  • Non-small-cell lung cancer
  • TKI (tyrosine kinase inhibitor)
  • UFT (UFUR, tegafur/uracil)

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. / Chen, Yuh Min; Perng, Reury Perng; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: Lung Cancer, Vol. 52, No. 3, 01.06.2006, p. 333-338.

Research output: Contribution to journalArticle

@article{7d416c22ac614d8fbd8bef54f5fc1906,
title = "A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy",
abstract = "Both gemcitabine and UFUR (UFT, tegafur/uracil) are effective agents against chemo-na{\"i}ve non-small-cell lung cancer (NSCLC). Their effectiveness in patients failing previous chemotherapy is uncertain. Our aim was to evaluate the efficacy of gemcitabine plus UFUR in NSCLC patients who failed previous platinum-based chemotherapy. Forty-five patients were enrolled. The performance status was 1 in 29 patients and 2 in 16 patients. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on days 1 and 8, plus oral UFUR 200 mg/m2/day from days 1 to 14 of every 3 weeks, to a maximum of six cycles, carried out in the outpatient clinic. One hundred and sixty cycles of treatment were given (mean 3.6 cycles per patient). Grade 3 or 4 toxicities included anemia in four patients, leukopenia in three patients, neutropenia in eight patients, thrombocytopenia in four patients, and fatigue in two patients. After two cycles of treatment, seven of 45 patients (15.6{\%}) had a partial response. The median survival was 13.2 months. Survival was better in those with a better performance status (p = 0.0006), in those with disease control using the present treatment (p < 0.0001), and in those who received Iressa or Tarceva as salvage therapy after failing the present treatment (p = 0.0054). In conclusion, salvage chemotherapy using gemcitabine plus UFUR is active, easy to use, and well tolerated in NSCLC patients who have failed previous chemotherapy. Further treatment with EGFR-TKI is also suggested when patients fail the present treatment.",
keywords = "EGFR (epidermal growth factor receptor), Gemcitabine, Non-small-cell lung cancer, TKI (tyrosine kinase inhibitor), UFT (UFUR, tegafur/uracil)",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2006.01.015",
language = "English",
volume = "52",
pages = "333--338",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Both gemcitabine and UFUR (UFT, tegafur/uracil) are effective agents against chemo-naïve non-small-cell lung cancer (NSCLC). Their effectiveness in patients failing previous chemotherapy is uncertain. Our aim was to evaluate the efficacy of gemcitabine plus UFUR in NSCLC patients who failed previous platinum-based chemotherapy. Forty-five patients were enrolled. The performance status was 1 in 29 patients and 2 in 16 patients. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on days 1 and 8, plus oral UFUR 200 mg/m2/day from days 1 to 14 of every 3 weeks, to a maximum of six cycles, carried out in the outpatient clinic. One hundred and sixty cycles of treatment were given (mean 3.6 cycles per patient). Grade 3 or 4 toxicities included anemia in four patients, leukopenia in three patients, neutropenia in eight patients, thrombocytopenia in four patients, and fatigue in two patients. After two cycles of treatment, seven of 45 patients (15.6%) had a partial response. The median survival was 13.2 months. Survival was better in those with a better performance status (p = 0.0006), in those with disease control using the present treatment (p < 0.0001), and in those who received Iressa or Tarceva as salvage therapy after failing the present treatment (p = 0.0054). In conclusion, salvage chemotherapy using gemcitabine plus UFUR is active, easy to use, and well tolerated in NSCLC patients who have failed previous chemotherapy. Further treatment with EGFR-TKI is also suggested when patients fail the present treatment.

AB - Both gemcitabine and UFUR (UFT, tegafur/uracil) are effective agents against chemo-naïve non-small-cell lung cancer (NSCLC). Their effectiveness in patients failing previous chemotherapy is uncertain. Our aim was to evaluate the efficacy of gemcitabine plus UFUR in NSCLC patients who failed previous platinum-based chemotherapy. Forty-five patients were enrolled. The performance status was 1 in 29 patients and 2 in 16 patients. Treatment consisted of gemcitabine 1000 mg/m2 intravenous infusion on days 1 and 8, plus oral UFUR 200 mg/m2/day from days 1 to 14 of every 3 weeks, to a maximum of six cycles, carried out in the outpatient clinic. One hundred and sixty cycles of treatment were given (mean 3.6 cycles per patient). Grade 3 or 4 toxicities included anemia in four patients, leukopenia in three patients, neutropenia in eight patients, thrombocytopenia in four patients, and fatigue in two patients. After two cycles of treatment, seven of 45 patients (15.6%) had a partial response. The median survival was 13.2 months. Survival was better in those with a better performance status (p = 0.0006), in those with disease control using the present treatment (p < 0.0001), and in those who received Iressa or Tarceva as salvage therapy after failing the present treatment (p = 0.0054). In conclusion, salvage chemotherapy using gemcitabine plus UFUR is active, easy to use, and well tolerated in NSCLC patients who have failed previous chemotherapy. Further treatment with EGFR-TKI is also suggested when patients fail the present treatment.

KW - EGFR (epidermal growth factor receptor)

KW - Gemcitabine

KW - Non-small-cell lung cancer

KW - TKI (tyrosine kinase inhibitor)

KW - UFT (UFUR, tegafur/uracil)

UR - http://www.scopus.com/inward/record.url?scp=33646364540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646364540&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.01.015

DO - 10.1016/j.lungcan.2006.01.015

M3 - Article

VL - 52

SP - 333

EP - 338

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -